NABH MITRA PROGRAM – Launch

The NABH MITRA Empanelment Programme has been officially launched to build a nationwide network of verified professionals and organisations (“MITRAs”) who will support hospitals with NABH Accreditation, Certification, and digital health transformation, especially across Tier 2, 3, and 4 cities in India.

The last date to submit applications for empanelment is October 10,2025

About the Programme

The initiative offers a structured, transparent framework for MITRAs—trusted companions to hospitals—who will guide healthcare organisations through quality improvement and digital enablement in line with NABH standards. Empanelled MITRAs will be listed on the NABH website with verified credentials and areas of expertise.

Categories of MITRAs

Digital MITRA: Supports hospitals in implementing NABH Digital Health Standards and IT enablement through structured digital health consultancy. Digital MITRA category has additional training and experience requirements

Organisational MITRAs: Support hospitals for both Full Accreditation and Entry-Level Certification.

Individual MITRAs: Independently support hospitals mainly for Entry-Level Certification.

Who Can Apply:

Individual MITRAs: Qualified professionals with at least one successful accreditation or certification support project and one NABH-certified professional (current assessors not eligible).

Organisational MITRAs: Registered companies, LLPs, trusts, societies, or proprietorship entities operational for at least one year, with experience supporting minimum three hospitals through accreditation or certification. Must have at least two NABH-certified professionals (current NABH assessors not eligible).

Application Process & Fees

i. Apply via the NABH online portal by October 10, 2025.
ii. Shortlisted candidates will be invited for interviews and required training.
iii.Empanelment fee for a three-year period: ₹20,000 + GST (Individual MITRA), ₹50,000 + GST (Organisational MITRA).
iv.Training program charges: ₹25,000 + GST for MITRA, ₹15,000 + GST for Digital MITRA (paid after selection)

Additional Information

i. MITRAs will play a key role in enabling hospitals to achieve NABH standards and strengthen India’s healthcare quality framework
ii. Empanelment does not imply endorsement or financial association by NABH.
iii.Maintaining high standards, transparency, and ethical conduct is compulsory.

Source: https://portal.nabh.co/Announcement/MEP_Concept.pdf

Workflows in the Age of AI Agents

Agent-based artificial intelligence is considered as the next leap in productivity. The logic is simple viz., assign a task to an agent and let it run. Yet the effectiveness of these systems depends far less on the sophistication of the code and far more on the clarity of the workflow they are given.

A workflow is the structured path through which work moves from start to finish. It defines the sequence of tasks, the hand-offs between people or systems, and the expected outcomes at each stage. Within this path, the process provides the backbone, setting out how each step should be performed, what standards apply, and how exceptions are to be managed. Without these foundations, the very data that agents rely on becomes unreliable. It is like attempting a Six Sigma project without stabilising the process first, because what you are measuring is so inconsistent that any optimisation is built on sand.

This is easy to see in practice. Consider a hospital admission workflow, which involves multiple departments, sensitive data, and critical timing. The journey begins with patient registration, where details are collected, a unique identity is created, and basic documentation such as identification or insurance papers is checked. The next vital step is financial clearance, either through insurance verification or collection of a deposit. If this is skipped or handled late, problems cascade downstream. Once financial clearance is complete, a medical assessment follows, triaging emergencies and routing others for physician review. Bed or room allocation then takes place, coordinated with housekeeping and transport to ensure readiness. Finally, clinical onboarding begins, with nurses briefing the patient, scheduling diagnostics, and updating the treating doctor through the hospital’s systems. From here, care and monitoring continue in a loop of data collection and coordination.

When this workflow is carefully mapped, each step is clear, responsibilities are defined, and the information flow is reliable. Insurance clearance cannot occur after room allocation, because the order is already locked. Registration cannot skip details, because every downstream task depends on them. The mapping creates discipline and ensures that the process holds together.

It is only on this foundation that AI agents add real value. They can automatically verify insurance coverage, trigger alerts when financial clearance is delayed, schedule diagnostic tests in line with physician orders, or update records in real time. But if the underlying workflow is inconsistent for instance, if insurance checks sometimes happen before and sometimes after admission the agent merely accelerates the inconsistency. Instead of solving the problem, it makes it worse.

The same logic applies to outside hospitals. In employee onboarding, for instance, the workflow may run from offer acceptance to first-day orientation, but unless the processes are consistent—laptop provisioning, payroll activation, mandatory training—the onboarding experience becomes fragmented, and any attempt to automate simply multiplies the unevenness.

AI agents are not shortcuts. They are multipliers. They multiply the clarity of a well-mapped workflow and the strength of well-defined processes. But they also multiply the confusion where structure is missing. The real question for organisations is not what agents can do, but whether the workflows and processes in place are clear enough for them to succeed.

The relevance and importance of this becomes even more clear on a ready of the article in McKinsey. They argue that productivity gains do not come from redrawing the structure chart but from rethinking the process itself. Their framework of four levers eliminate, synchronize, streamline, and automate offers a practical way to make workflows more resilient and effective. The traditional disciplines of process mapping and standardisation, sometimes dismissed as dated, are in fact more critical than ever in the age of AI agents. To eliminate is to cut away what is redundant, whether duplicate reports, excessive meetings, or unnecessary checkpoints. To synchronize is to ensure that information flows across boundaries without delay, so that decisions are taken in context and in time. To streamline is to reduce clutter, focusing on what matters most to decision quality instead of drowning people in backward-looking commentary or irrelevant granularity. And to automate is to use digital tools to take over routine work, allowing human judgment and creativity to come to the fore.

Placed against the earlier examples, the relevance is obvious. In hospital admissions, eliminating unnecessary checkpoints, synchronising across clinical and financial functions, streamlining reporting to focus on patient readiness, and automating insurance checks would not only reduce errors but also accelerate outcomes. In employee onboarding, the same four levers would prevent duplication, improve hand-offs, and allow AI agents to truly enhance the experience rather than amplify confusion.

Seen this way, the emphasis on process is not old-fashioned bureaucracy but the very foundation of modern productivity. AI becomes a companion rather than a replacement. It multiplies whatever exists discipline or disorder and the responsibility lies with organisations to ensure that what exists is well designed. Only then can agents elevate performance, reduce wasted effort, and create sustainable value.

Industry Information update : Sector-wise Compendiums of Indian Standards

BIS Unveils 130 Sector-wise Compendiums of Indian Standards to Enhance Industry and Consumer Awareness

The Bureau of Indian Standards (BIS) has released a comprehensive collection of 130 sector-specific compendiums of Indian Standards, now accessible on the BIS portal.

Organized by industry sectors and product/service categories, these compendiums serve as consolidated reference guides for a wide range of stakeholders, including regulatory authorities, industry professionals, academic institutions, and consumer organizations.

Stakeholders can access the compendiums at
https://services.bis.gov.in/php/BIS_2.0/bisconnect/compendium_of_indian_standards_dept_wise

Please scan the QR code given below to download :

Source: https://services.bis.gov.in/php/BIS_2.0/bisconnect/compendium_of_indian_standards_dept_wise

Industry update: Constitution of Medical Device related adverse Event Committee in Medical Colleges

The National Medical Commission (NMC) public notice, dated July 13, 2025, addresses the monitoring, assessment, and prevention of adverse events associated with medical devices through the constitution of a Medical Device related Adverse Event Committee (MDAEC) in each medical college.

Here’s a breakdown of the advisory:

Intent of the Advisory:

The core intent of this advisory is to enhance patient safety and improve the quality of healthcare delivery by systematically collecting, analyzing, and responding to adverse events related to medical devices. It acknowledges that medical devices are crucial in modern healthcare but can cause harm, necessitating a robust monitoring system. The advisory emphasizes the integration of medical colleges into the Materiovigilance Programme of India (MvPI), launched in 2015 by the Ministry of Health and Family Welfare (MoHFW), to monitor these adverse events and risks nationwide. This program aims to provide data to the Central Drugs Standard Control Organization (CDSCO) to support regulatory action and guide improvements in clinical practice.

Role of Medical Colleges:

Medical colleges are identified as ideal hubs for Materiovigilance due to their diverse patient populations and access to advanced healthcare technologies.

The advisory outlines several strategic advantages for medical colleges becoming a Medical Device Adverse Events Monitoring Centre (MDMC), including:

Academic Recognition: Enhancing the institution’s stature as a contributor to national public health and regulatory science.
Professional Development: Providing faculty and students hands-on exposure to post-market surveillance, risk assessment, and patient safety.
Infrastructure Enhancement: Gaining access to MvPI resources, training modules, and national-level collaboration.
Policy Influence: Offering opportunities to contribute to evidence-based recommendations and medical
device regulations.
Patient Safety: Ensuring early detection and response to device malfunctions, directly improving clinical outcomes.

Key Directives for Medical Colleges:

The advisory mandates the following actions for all medical institutions:

Establishment of MDAEC: Each medical institution is advised to set up a committee to monitor adverse events related to medical devices.
Registration with IPC: This committee must be registered with the Indian Pharmacopoeia Commission (IPC). The enrollment form is available on the IPC website.
Website Disclosure: The medical institution’s website must indicate the name of the Coordinator/Convenor and additional members of the committee.
Chairperson: The Medical Superintendent will ordinarily be the Chairperson of this committee.
Registration Date: The website should also indicate the date of MDAEC registration.
Pharmacovigilance Committee Update: Institutions are also reminded to update the names of Pharmacovigilance Committee members on their website.

Timeline: This process has to be completed before July 31, 2025.

Source:https://www.nmc.org.in/MCIRest/open/getDocument?path=/Documents/Public/Portal/LatestNews/Public%20Notice%20dt%2013-07-2025.pdfhttps://www.nmc.org.in/MCIRest/open/getDocument?path=/Documents/Public/Portal/LatestNews/Public%20Notice%20dt%2013-07-2025.pdf

Industry Information Update – BIS – Sector wise Calendar for Upcoming Webinars

Bureau of Indian Standards is organising Sector specific awareness programs

In order to spread the awareness among the concerned stakeholders, manufacturers, importers and common consumers BIS is organising ‘Interactive lecture series and Sector-wise webinar’ on the below mentioned topics.

Manufacturers including MSMEs are requested to attend the above webinars based on their respective business interests for a particular sector.

Participation in these webinars does not require any preregistration and can be joined conveniently and remotely through Computer / Laptops / Mobiles.

The link for joining these webinars are hosted well in advance on BIS Website: www.bis.gov.in

Source: https://www.bis.gov.in/

Industry Information Update – HOSPEX–QAI Quality Culture Award 2025

4th Edition of  HOSPEX Healthcare Expo cum Conferences will be held at Kochi, Kerala from Aug 22nd – 24th 2025. This is Kerala’s first B2B Medical Expo which will take place at KINFRA International Exhibition Centre, Kakanad, Kochi, Kerala

As a part of the Expo, to encourage, nurture the Culture of Practicing Quality in Small Hospitals, Hospex-QAI Quality Culture Award 2025 is designed this year.

About the Award:

The award is a joint initiative of HOSPEX India and QAI.

This award is a recognition of the Quality Focus that is built in Small Hospitals and the efforts taken by Small Hospitals to make Quality a Culture in their clinical settings.

For any Practice to become a Culture needs lot of commitment in any organisation. This award is created to motivate healthcare facilities to come forward and pitch their Quality Practices which have become a Culture in their settings.

About HOSPEX:       

Hospex is the initiative of Trithvam Integris, a company that specialises in managing Health and Medical Fair Events. Hospex is solely focused on digital health, healthcare and organising conferences for the medical industry by a group of doctors.

HOSPEX 2025 is the only Medical & Healthcare Exhibition in Kerala targeting Hospitals, Other Healthcare organisations, Medical Device Manufacturers, Pharmaceutical Manufacturers, Startups, Innovators in Health Tech and Med tech space.

The core focus of HOSPEX Healthcare Expo 2025 (Fourth Edition) is Medical Knowledge dissemination thereby hosts multitude of conferences focused on the futuristic trends in the medical industry. These conferences provide attendees with the opportunity to learn about new products and technologies, network with other professionals in the field, and stay up-to-date on the recent and futuristic developments in the industry

About QAI – Quality & Accreditation Institute

Quality and Accreditation Institute (QAI) is an International Accreditation Body that provides Accreditation/ Certification to Healthcare Organisations (Hospitals, Clinics, Dental centres, Eye Clinics, Imaging centres, IVF centres, Dialysis centres, Home Care, Stroke centres, Telehealth services, Hair Transplant Centres, Bone Marrow Transplant centres, Rehabilitation centres, Ambulatory care centres etc.).

QAI provides a platform to stakeholders including professionals and organisations, associated with Quality in any way, to share their wisdom and Knowledge in order to make healthcare services delivering better outcomes.

QAI is closely working with stakeholders including Government agencies to support accredited healthcare facilities in terms of empanelment and other benefits.

Target Segment:

Any healthcare facility such as Hospitals, Clinics, Dental centres, Eye Clinics, Imaging centres, IVF centres, Dialysis centres, Home Care providers, Stroke centres, Telehealth services, Hair Transplant Clinics, Bone Marrow Transplant centres, Rehabilitation centres, Ambulatory care centres etc.).

Wellness Centres offering AYUSH Services

Applicants can be from Private or Government settings.

Eligibility Criteria:

  • Applicant must have implemented a Quality Management System/ Patient Safety Program/ any Certification or Accreditation Program for a minimum period of last 3 years continuously
  • QAI accredited healthcare facility will be given preference
  • Applicant can be from any part of India

Application Form Content:

  • To be filled in the format given
  • General Information about the Healthcare facility
  • Specific information about Quality Practices/ Certifications / Accreditation (Evidences to be submitted to support any such claims)
  • 2 case studies/ examples to demonstrate improvement/ patient safety in last 3 years
  • Language for submission – English

Application Fee:

  • Rs. 1180/- (including 18% GST) for each application

    To be payable to HOSPEX India’s account as shared below:

    Tritvam Integris Pvt. Ltd.
    GST No: 32AAJCT2250M1ZA
    Tritvam Integris, Jyothi Trade Centre, Chettupuzha, PO,  Thrissur – 680 012

Application Submission Date:
Last date for submitting applications: 10 August 2025.

Completed Application including payment proof to be mailed to:

Ms. Chandni Rohila

Accreditation Officer
Quality & Accreditation Institute (QAI)
709, Wave Silver Tower, Sector 18, Noida-201301, India
Ph. No.: +911206664981
M: +91 8287841146
Email – chandni@qai.org.in

Terms and Conditions:

  • Only completed applications will be taken up for evaluation.
  • Jury will comprise of experienced professionals with healthcare operations, management, quality, clinical background
  • Only one application per location is acceptable.
  • Applicants can save the completed application and all evidences on a google drive folder and can share the folder access link to QAI through email to chandni@qai.org.in.
  • Applications submitted after the last date will not be entertained.
  • Jury will evaluate the applications and decide on the winners of the Award.
  • Shortlisted applicants may be called for virtual presentation, if needed.
  • Winners will be announced by 12 August 2025.
  • Winers will have to travel to Kochi (Cochin), to collect their Awards in an event to be held on 23 August 2025.
  • Organisers will not make any travel, stay arrangements and winners have to make their own arrangements.
  • Decision of the Jury shall be final and binding on all.

Source: https://hospex.in/

Industry Update – New Draft Guidelines on Similar Biologics 2025 Released

The CDSCO and DBT have jointly released the much-anticipated Draft Guidelines on Similar Biologics 2025. This marks a significant update over the 2016 version, incorporating global regulatory trends and streamlining the approval pathway for biosimilars in India.

Key updates include:

🔹 Enhanced focus on Quality by Design (QbD)
🔹 Revised preclinical and clinical study requirements
🔹 Stronger post-marketing surveillance framework
🔹 Greater alignment with WHO, EMA, and USFDA standards

This is a step forward in strengthening India’s position as a global hub for affordable, high-quality biologics.

The Draft Guidelines is now being placed in the public domain for inviting comments/suggestions from concerned stakeholders. All interested stakeholders are requested to provide comments/suggestions within the window of 30 days at biological@cdsco.nic.in in word document as per the format given below.

The suggestions/comments received on the above email address within the 30 days shall be taken into consideration for finalisation of the draft Guidance document.  

Stakeholder’s Comments format

Name and Designation: 
Firm Name: 

S.No.Page NoLine NoSection/Sub- section/ HeadingCurrent textProposed TextExplanation/Reference
       
       
       

Source: https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadPublic_NoticesFiles/Draft%20Guidelines%20on%20Similar%20Biologics%202025.pdf

Industry update – FAQs-CDSCO

Medical Device Division of CDSCO (Central Drugs Standard Control Organization) releases FAQ document on periodical basis to clarify the frequently raised questions by industry and other stakeholders .

Latest FAQ Document was released on 3rd April 2025 . This FAQ document is released for Medical Device Sector , not for IVDs.
Doc No.:CDSCO/FAQ/MD/01/2024. Addendum No.: 01. Date: 03.04.2025

CDSCO’s Note :

The replies to the FAQs are aimed only for creating public awareness about Medical Devices Regulation by CDSCO and are not meant to be used for legal or professional purposes. The readers are advised to refer to the statutory provisions of Drugs and Cosmetics Act & Rules and respective Guidelines / Clarifications issued by CDSCO from time to time for all their professional needs.

The document is released as an Addendum to FAQ on Medical Devices Rules, 2017:

Questions covered in the FAQ are listed below :

  • Whether the manufacturer or importer need to conduct the Biocompatibility test on the all applied products?
  • Whether the manufacturer can release the sterile medical device to the market based on parametric release?
  • Whether for a Medical device which is supplied in non-sterile state, the expiry/shelf life is mandatory on its label?
  • Whether the validation and QC data of medical device generated by the manufacturer for the medical device which is marketed in the country prior to implementation of the mandatory licensing regime under MDR, 2017 can be considered for grant of manufacturing license in the country?
  • In case of Change of constitution of the company/firm holding the manufacturing license under the MDR-2017, whether fresh license is required?
  • In case of Change of constitution of the company/firm holding the import license under the MDR-2017, whether fresh license is required?
  • In case of Change of constitution of the company/firm holding the registration certificate under the MDR-2017, whether fresh registration is required?
  • Whether the applicant can submit a single application for multiple actual manufacturing site for obtaining import license?
  • In case of change in the location of manufacturing site of the manufacturer whether a fresh license is required?
  • What is a ‘non-sterile medical device’ ?
  • What are the packaging and labelling requirements for a ‘non-sterile medical device’ if it is intended to be sterilized before use?
  • What is a ‘sterile medical device’ ?
  • Whether wholesale licence in Form 20B/21B under Drug Rules, 1945 or Registration certificate in Form MD-42 under Medical Devices Rules,2017 is mandatory for Class A (non-sterile and non-measuring) medical devices?
  • What is the regulatory pathway to be followed for obtaining manufacturing/ import license for medical device under MDR-2017?
  • Whether the manufacturer of medical device require to obtain ISO 13485:2016 certificate for obtaining manufacturing license under MDR-2017?
  • In case of Import of medical devices, whether Brand name of a medical device owned by an Indian authorized agent can be mentioned on the application for import in Form MD-14?

    To read the replies shared for each of the FAQs listed above, read the FAQ document released by CDSCO which can be downloaded from the button below

Source of the Document released by CDSCO :
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/Addendum-0152.pdf

Industry Update – MoHFW Notification

Ministry of Health and Family Welfare has released a gazette notification notifying the new rules that may be called the Drugs and Cosmetics (Compounding of Offences) Rules, 2025. The rules are framed by the Central Government using the powers conferred by the Drugs and Cosmetics Act, 1940.

The notification introduces rules under an existing act, under section 33 of the Drugs and Cosmetics Act, 1940 (23 of 1940).

These rules provide a framework for “compounding of offences” under the Drugs and Cosmetics Act, 1940. This means that instead of going through full prosecution, certain offences might be resolved by paying a specified amount (compounding amount). The rules outline the process for applying for compounding, the authorities involved, and the conditions for granting immunity from prosecution.

Key highlights of the Drugs and Cosmetics (Compounding of Offences) Rules, 2025 notification:

Compounding of Offences: The primary focus is to establish rules for compounding certain offences under the Drugs and Cosmetics Act, 1940, offering an alternative to traditional prosecution.  

Application Process: The rules detail how an applicant (a company or person involved in the pharma industry) can apply for compounding of an offence. This can be done before or after prosecution begins.  

Compounding Authority: The notification defines the “compounding authority” and how they are appointed by the Central or State Government to manage the compounding process.  

Procedure: It outlines the step-by-step procedure the compounding authority must follow, including gathering reports and making decisions on whether to allow compounding.  

Immunity from Prosecution: The rules explain the conditions under which the compounding authority can grant immunity from prosecution to an applicant.  

Withdrawal of Immunity: The notification also specifies the circumstances under which this granted immunity can be withdrawn.  

Form for Application: The inclusion of a specific form for applying for compounding of offences

Why the need for “Compounding of Offences” ?

The Jan Vishwas (Amendment of Provisions) Act, 2023, aims to decriminalize various offenses in 42 Central Acts, enhancing ease of doing business and living by reducing compliance burdens. It accomplishes this by removing imprisonment and/or fines in many provisions, replacing them with penalties or enhancing existing fines. 

Key features and objectives of the Jan Vishwas Act include:

  • Decriminalization:The Act decriminalizes 183 provisions across 42 Central Acts, which are administered by 19 Ministries/Departments. 
  • Enhanced Ease of Doing Business:The Act aims to simplify compliance for businesses by removing or modifying existing criminal penalties. 
  • Trust-Based Governance:By decriminalizing certain offenses, the Act seeks to foster a more trust-based environment for businesses. 
  • Pragmatic Penalties:The Act introduces mechanisms for adjudicating officers and appellate authorities, ensuring penalties are commensurate with the severity of the offense. 
  • Flexibility in Enforcement:The Act allows for compounding of certain offenses, providing an alternative to full-fledged prosecution. 
  • Focus on Specific Acts:The Act addresses provisions in various Acts, including those related to intellectual property, media, and other sectors. 

Drugs and Cosmetics Act, 1940 Amendment: The Drugs and Cosmetics Act, 1940 is one of the acts amended by the Jan Vishwas Act.

Implementation of Jan Vishwas Act’s Intent: The Drugs and Cosmetics (Compounding of Offences) Rules, 2025, can be seen as a mechanism to implement the changes brought about by the Jan Vishwas Act to the Drugs and Cosmetics Act, 1940. It provides the specific procedures and framework for how these offenses will be dealt with, in alignment with the intent of decriminalization and promoting ease of doing business.

Overall, the Jan Vishwas Act aims to create a more business-friendly and less punitive environment by decriminalizing certain offenses and rationalizing legal provisions across various sectors. 

Hence the new Rules on Compounding of Offences under Drugs & Cosmetics Act may have originated from the recent amendments made to Jan Vishwas (Amendment of Provisions) Act 2023.

In essence, the Jan Vishwas Act provides the legislative amendment to allow for decriminalization, and the Drugs and Cosmetics (Compounding of Offences) Rules, 2025, provides the procedural rules for implementing that change through compounding of offenses.

Industry Update – Electronics Component Manufacturing Scheme (ECMS)

In a major step toward boosting the electronics sector and making India self-reliant, the Ministry of Electronics and Information Technology (MeitY) has officially launched the Electronics Component Manufacturing Scheme (ECMS) on 8th April 2025.

This move is a part of India’s broader push to develop a strong domestic manufacturing ecosystem and reduce reliance on imports — in line with the vision of Atmanirbhar Bharat

What is ECMS?

The Electronics Component Manufacturing Scheme (ECMS) is a government-backed initiative designed to:

i. Strengthen India’s integration with Global Value Chains (GVCs)
ii Build a robust electronics components and sub-assemblies manufacturing ecosystem.
iii.Attract global and domestic investments.
iv.Enhance Domestic Value Addition (DVA).

Key Objectives


i. Create new employment opportunities, especially for India’s youth.
ii. Create an enabling environment for manufacturing critical electronic components and sub-assemblies.
iii. Address challenges like high capital investment needs, long gestation periods, and lack of economies of scale.
iv. Reduce import dependence by promoting local production of key electronics parts.

Features of the Scheme
Investment eligibility window for CapEx incentives: 5 years from project approval.

Incentive Types:

📈 Turnover-linked Incentive: Based on incremental sales over the base year.
🏭 Capital Expenditure (CapEx) Incentive: Based on eligible capital investment.
🔄 Hybrid Incentive: A combination of both turnover and capex incentives.

Focus Areas (Target Segments):

i. Display module sub-assemblies
ii. Camera module sub-assemblies
iii. Li-ion cells for digital applications (excluding storage and mobility)
iv. Multi-layer and flexible PCBs
v. Non-SMD passive components
vi. Enclosures and capital goods used in electronics manufacturing

Budget Outlay: ₹22,919 crore, including administrative expenses.

Duration:

i. Turnover-linked incentives available for up to 6 years.
ii. Investment eligibility window for CapEx incentives: 5 years from project approval

Eligibility Criteria :

i. Applicants should have strong global/domestic ESDM (Electronics System Design and Manufacturing) capabilities.
ii. Both greenfield (new) and brownfield (existing) projects are eligible.
iii.Companies must submit separate applications for each target product segment.
iv.Must meet minimum investment, sales, and employment growth thresholds.

Base Year:

i. Companies can opt for a gestation year (FY 2025-26) if required.
ii.Financial Year 2024-25 is the default base year for calculating incremental sales.

Expected Impact :

With a focus on sub-assemblies and critical components, the ECMS aims to:
i. Create large-scale job opportunities, especially in the electronics manufacturing sector.
ii.Decrease imports and boost local manufacturing.
iii.Integrate Indian companies into global supply chains.
iv.Position India as a major hub for electronics exports.

The Electronics Component Manufacturing Scheme is a strategic move to secure India’s electronics supply chain and foster long-term economic growth. By incentivizing investment in critical manufacturing areas, India is not only aiming to meet its domestic demand but also establish itself as a trusted global manufacturing partner.

The future of electronics manufacturing in India looks bright, and the ECMS is poised to be a game-changer in India’s journey toward a $1 trillion digital economy!

Source: https://www.meity.gov.in/static/uploads/2025/04/e31d6fbd4044f8794f58157ba685e1ad.pdf